Profile data is unavailable for this security.
About the company
Rohto Pharmaceutical Co Ltd is a Japan-based company primarily engaged in the manufacture and sale of eye care (eye drops, eyewash), skin care (external medications, lip balm, sunscreen, functional cosmetics), oral medication (gastrointestinal medicines, herbal medicines, supplements), and other products and services (in vitro diagnostic reagents) in the health and beauty care field. The Company operates through four regional segments. The Japan segment manufactures and sells eye care, skin care, oral medication, and other products (services). The Americas segment and the Europe segment mainly manufacture and sell skin care products (services). The Asia segment mainly manufactures and sells eye care and skin care products (services), as well as oral medication products (services).
- Revenue in JPY (TTM)335.80bn
- Net income in JPY34.48bn
- Incorporated1949
- Employees9.14k
- LocationRohto Pharmaceutical Co Ltd1-8-1, Tatsumi-Nishi, Ikuno-kuOSAKA-SHI 544-8666JapanJPN
- Phone+81 667581231
- Websitehttps://www.rohto.co.jp
More ▼
Mergers & acquisitions
| Acquired company | 4527:TYO since announced | Transaction value |
|---|---|---|
| Thann Oryza Co Ltd | -4.50% | -- |
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mochida Pharmaceutical Co Ltd | 111.92bn | 6.42bn | 136.28bn | 1.51k | 20.67 | 0.966 | 14.52 | 1.22 | 181.16 | 181.16 | 3,156.95 | 3,876.77 | 0.6427 | 1.67 | 3.02 | 74,214,190.00 | 3.69 | 4.50 | 4.47 | 5.44 | 48.43 | 52.49 | 5.74 | 6.87 | 2.85 | -- | 0.0678 | 43.01 | 2.21 | 0.6516 | 25.03 | 4.34 | 1.98 | 0.00 |
| Kaken Pharmaceutical Co Ltd | 75.66bn | -3.83bn | 186.27bn | 1.13k | -- | 1.10 | -- | 2.46 | -97.11 | -97.11 | 1,980.56 | 3,850.39 | 0.4091 | 1.86 | 2.80 | 67,195,380.00 | -2.07 | 5.99 | -2.42 | 6.87 | 53.09 | 56.17 | -5.06 | 12.91 | 3.21 | -- | 0.0257 | 59.58 | 30.52 | 1.05 | 73.77 | -6.36 | 14.81 | 0.00 |
| Towa Pharmaceutical Co Ltd | 266.67bn | 20.65bn | 195.25bn | 4.79k | 9.04 | 1.04 | 4.64 | 0.7322 | 419.38 | 419.38 | 5,417.06 | 3,653.68 | 0.5776 | 1.51 | 4.12 | 55,694,650.00 | 4.47 | 3.89 | 5.45 | 5.07 | 36.38 | 37.81 | 7.74 | 6.61 | 1.51 | 44.31 | 0.5678 | 21.52 | 13.89 | 18.65 | 17.39 | 5.53 | 46.23 | 9.73 |
| Kissei Pharmaceutical Co Ltd | 95.29bn | 14.14bn | 215.49bn | 1.78k | 13.72 | 0.8869 | 11.41 | 2.26 | 337.47 | 337.47 | 2,274.29 | 5,220.29 | 0.3748 | 1.85 | 2.83 | 53,596,180.00 | 5.62 | 4.26 | 6.19 | 4.60 | 48.21 | 48.59 | 14.99 | 14.30 | 3.42 | -- | 0.0058 | 32.41 | 16.87 | 6.91 | 7.18 | 33.54 | 31.04 | 13.97 |
| Sawai Group Holdings Co Ltd | 200.00bn | 309.00m | 277.23bn | 3.31k | 3,774.31 | 1.57 | 17.42 | 1.39 | 0.636 | -11.40 | 1,703.92 | 1,531.41 | 0.5559 | 1.24 | 4.09 | 60,422,060.00 | 0.0862 | -0.2327 | 0.1143 | -0.3187 | 29.39 | 32.95 | 0.155 | -0.475 | 0.812 | 0.7435 | 0.3737 | 191.65 | 6.88 | 0.7009 | -87.38 | -35.38 | 8.65 | 4.11 |
| Tsumura & Co | 189.50bn | 29.01bn | 310.10bn | 4.27k | 10.44 | 0.9863 | 7.27 | 1.64 | 387.15 | 387.15 | 2,524.84 | 4,095.99 | 0.374 | 0.7106 | 2.41 | 44,357,680.00 | 6.01 | 5.53 | 8.06 | 6.85 | 47.60 | 49.39 | 16.06 | 14.50 | 1.45 | -- | 0.2856 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
| Nippon Shinyaku Co Ltd | 166.05bn | 29.85bn | 351.54bn | 2.24k | 11.29 | 1.19 | 9.71 | 2.12 | 443.17 | 443.17 | 2,465.26 | 4,211.80 | 0.5421 | 1.17 | 3.19 | 74,028,980.00 | 9.75 | 10.89 | 10.81 | 12.74 | 67.29 | 63.93 | 17.98 | 17.67 | 4.04 | -- | 0.0089 | 30.58 | 8.08 | 6.56 | 25.94 | 14.06 | 80.48 | 7.59 |
| Hisamitsu Pharmaceutical Co Inc | 159.27bn | 19.99bn | 474.67bn | 2.80k | 22.80 | 1.65 | 17.25 | 2.98 | 276.99 | 276.99 | 2,208.13 | 3,837.32 | 0.4704 | 2.64 | 3.42 | 56,901,390.00 | 6.04 | 4.34 | 7.25 | 4.99 | 59.05 | 57.83 | 12.84 | 10.32 | 3.28 | -- | 0.0086 | 50.29 | 10.09 | 2.04 | 55.76 | 3.08 | 29.89 | 0.7127 |
| Santen Pharmaceutical Co Ltd | 287.99bn | 30.60bn | 553.51bn | 3.85k | 18.66 | 1.95 | 11.36 | 1.92 | 92.03 | 92.03 | 865.27 | 880.97 | 0.7205 | 2.26 | 4.18 | 74,823,070.00 | 7.63 | 3.94 | 9.43 | 4.93 | 56.89 | 58.97 | 10.59 | 6.01 | 1.89 | -- | 0.1757 | 71.86 | -0.6494 | 4.43 | 36.09 | 8.94 | 3.61 | 5.92 |
| Rohto Pharmaceutical Co Ltd | 335.80bn | 34.48bn | 614.65bn | 9.14k | 17.55 | 2.05 | 11.81 | 1.83 | 148.28 | 148.28 | 1,444.67 | 1,272.14 | 0.7768 | 2.32 | 4.55 | 36,723,640.00 | 8.02 | 8.59 | 11.20 | 11.70 | 56.06 | 57.78 | 10.33 | 10.57 | 1.43 | -- | 0.1452 | 21.12 | 13.95 | 10.38 | 0.2263 | 15.01 | 10.42 | 22.59 |
| Sumitomo Pharma Co Ltd | 453.40bn | 110.09bn | 951.38bn | 3.83k | 8.63 | 3.29 | 7.22 | 2.10 | 277.11 | 277.11 | 1,141.22 | 727.28 | 0.5438 | 1.95 | 3.99 | 118,318,100.00 | 13.20 | -5.49 | 23.02 | -8.49 | 59.24 | 67.88 | 24.28 | -13.24 | 1.01 | 4.17 | 0.4726 | -- | 26.79 | -3.75 | 107.50 | -10.32 | -0.4856 | -- |
Data as of Feb 13 2026. Currency figures normalised to Rohto Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
22.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| MFS International (UK) Ltd.as of 31 Dec 2025 | 12.28m | 5.20% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 7.32m | 3.10% |
| Nomura Asset Management Co., Ltd.as of 08 Jan 2026 | 7.27m | 3.08% |
| Asset Value Investors Ltd.as of 31 Oct 2025 | 6.05m | 2.56% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 4.63m | 1.96% |
| SPARX Asset Management Co., Ltd.as of 31 Dec 2025 | 3.62m | 1.53% |
| Amova Asset Management Co., Ltd.as of 09 Jan 2026 | 3.23m | 1.37% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2025 | 3.20m | 1.36% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 2.67m | 1.13% |
| FIL Investments (Japan) Ltd.as of 22 Sep 2025 | 2.33m | 0.99% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
